• FirefoxUpgrade to the new Firefox »
  •  Dow Up0.15% Nasdaq Up0.36%

    Peregrine Pharmaceuticals, Inc. (PPHM)

    -NasdaqCM
    1.42 Down 0.04(2.74%) Dec 19, 4:00PM EST
    |After Hours : 1.42 0.00 (0.00%) Dec 19, 4:48PM EST
    Add to Portfolio
    ProfileGet Profile for:
    Peregrine Pharmaceuticals, Inc.
    14282 Franklin Avenue
    Tustin, CA 92780
    United States - Map
    Phone: 714-508-6000
    Website: http://www.peregrineinc.com

    Details 
    Index Membership:N/A
    Sector:Healthcare
    Industry:Biotechnology
    Full Time Employees:180

    Business Summary 

    Peregrine Pharmaceuticals, Inc., a biopharmaceutical company, is engaged in the research and development of novel monoclonal antibodies for the treatment and diagnosis of cancer in the United States. Its lead immunotherapy candidate, bavituximab, is in Phase III development for the treatment of second-line non-small cell lung cancer along with various investigator-sponsored trials evaluating other treatment combinations and additional oncology indications. The company is also evaluating its lead molecular imaging agent, 124I-PGN650, in an exploratory clinical trial for the imaging of various solid tumor types. In addition, it provides contract manufacturing services ranging from cell line development to commercial current good manufacturing practice biomanufacturing to third-party clients. The company has various license agreements with the University of Texas Southwestern Medical Center at Dallas; Genentech, Inc.; Avanir Pharmaceuticals, Inc.; Lonza Biologics; Affitech A/S; and Merck KGaA. Peregrine Pharmaceuticals, Inc. was founded in 1981 and is headquartered in Tustin, California.

    Key Statistics


    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Peregrine Pharmaceuticals, Inc.

    Corporate Governance 
    Peregrine Pharmaceuticals, Inc.’s ISS Governance QuickScore as of Dec 1, 2014 is 10. The pillar scores are Audit: 2; Board: 8; Shareholder Rights: 9; Compensation: 10.
    Brought to you by Institutional Shareholder Services (ISS)

    Key Executives 
     PayExercised
    Mr. Steven W. King , 50
    Chief Exec. Officer, Pres, Director, Chief Exec. Officer of Avid Bioservices Inc and Pres of Avid Bioservices Inc
    967.00K0.00
    Mr. Paul J. Lytle CPA, 46
    Chief Financial Officer and Principal Accounting Officer
    607.00K0.00
    Mr. Mark R. Ziebell J.D., 50
    VP, Gen. Counsel and Corp. Sec.
    540.00K0.00
    Dr. Shelley P. M. Fussey Ph.D., 48
    VP of Intellectual Property
    493.00K0.00
    Mr. Joseph S. Shan M.P.H., 41
    VP of Clinical & Regulatory Affairs
    445.00K0.00
    Amounts are as of Dec 31, 2014 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders